摘要:目的: 系統評價非布索坦治療痛風的療效及安全性。 方法 :計算機檢索PubMed、EMBASE、SCI、CBM、CNKI、VIP、萬方數據庫及Cochrane圖書館,手工補充檢索;納入非布索坦治療痛風的隨機對照試驗(RCT);進行方法學質量評價和Meta分析。 結果 :共納入3個RCT(受試者1985例),A級文獻1篇,B級文獻2篇。Meta分析結果顯示:最后3月血清尿酸(SU)持續低于60 mg/dl患者數、隨訪結束時SU低于60 mg/dl患者數非布索坦組與對照組差異均有統計學意義;治療相關不良事件發生數與安慰劑組差異無統計學意義,與別嘌呤組差異有統計學意義。 結論 :基于當前證據,非布索坦治療痛風,能有效降低SU含量,減少治療相關不良事件發生率。
Abstract: Objective: Assessing the effectiveness and safety of febuxostat for the treatment of gout. Methods :Randomized controlled trails(RCT) of febuxostat for the treatment of gout were gathered from the Cochrane Library、PubMed、EMBASE、SCI、CBM、CNKI、VIP、Wangfang Database, other relative researches were handsearched, each RCT was methodological quality evaluated, then analyzed by software RevMan50 Results :A total of 3 RCTs were collected (involving 1985 subjects); 1 was graded A, 2 were B; according to the Metaanalysis: the differences of subjects with last 3 monthly serum urate(SU)＜60mg/dl and subjects with SU＜60mg/dl at final visits were significant; treatmentrelated adverse events between febuxostat and allopurinol was significant different, but not significant difference between febuxostat and placebo. Conclusion : According to the evidence currently, febuxostat could reduce SU and the episodes of treatmentrelated adverse events.

Citation： ZHANG Yan.. Effectiveness and Safety of Febuxostat for the Treatment of Gout: A Meta Analysis. West China Medical Journal, 2009, 24(10): 2599-. doi: Copy

Copyright ? the editorial department of West China Medical Journal of West China Medical Publisher. All rights reserved